Skip to main content
Premium Trial:

Request an Annual Quote

Cast Your Vote (Though It May Not Matter)

Newsweek's Mary Carmichael is polling her readers: should she "take an at-home gene test"? In the first post of her weeklong series, Carmichael ponders her own ambivalence to DTC genetic testing, and says that "there’s a DNA-collection kit on my desk now, taunting me — because although I bought the thing, I still can't decide whether I actually want to use it." Throughout the week, the author will post answers to her burning DTC questions from expert contributors, all the while polling her readership as to whether she should send along her spit. She asks that contributors "keep it short and sweet," admit their biases — namely, disclose financial stakes, if any, in the industry — and to not "insult [her] intelligence." Those interested can follow her decision-making process on Twitter (#DNAdilemma), she says, adding a disclaimer that "even if our reader poll ends up being 99 percent pro-test, I may decide to abstain." The Newsweek editor says she'll make her decision on Friday.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.